The Alliance A021101 trial is a phase II clinical trial designed to investigate the use of neoadjuvant chemotherapy followed by surgery for patients with borderline resectable pancreatic cancer. Borderline resectable pancreatic cancer is a type of pancreatic cancer that is located near major blood vessels, making it difficult to remove through surgery. The goal of the trial is to determine whether neoadjuvant chemotherapy can shrink the tumor and make it more likely that the tumor can be removed with surgery.
The trial enrolls patients with borderline resectable pancreatic cancer who have not received prior chemotherapy or radiation therapy for their cancer. Patients receive neoadjuvant chemotherapy with the FOLFIRINOX regimen, which is a combination of four chemotherapy drugs: fluorouracil, leucovorin, irinotecan, and oxaliplatin. FOLFIRINOX has been shown to be effective in treating advanced pancreatic cancer and is now being tested in earlier-stage disease.
After three months of chemotherapy, patients undergo imaging studies to assess the response of their tumor to treatment. If the tumor has shrunk or become stable, patients undergo surgery to remove the tumor. If the tumor has not responded to treatment, patients continue to receive chemotherapy until the tumor can be safely removed.
The primary endpoint of the trial is the proportion of patients who undergo successful surgery with negative margins (meaning no cancer cells are seen at the edges of the tissue that was removed). Secondary endpoints include the overall survival rate, disease-free survival rate, and safety and tolerability of the neoadjuvant chemotherapy regimen.
The trial has several inclusion and exclusion criteria to ensure the safety and efficacy of the treatment. Patients must be at least 18 years old and have borderline resectable pancreatic cancer that has not spread to other parts of the body. Patients with certain medical conditions, such as liver or kidney disease, or who have received prior chemotherapy or radiation therapy are excluded from the trial.
The Alliance A021101 trial has the potential to improve the treatment and outcomes for patients with borderline resectable pancreatic cancer. By testing the use of neoadjuvant chemotherapy followed by surgery, the trial aims to increase the number of patients who can undergo successful surgery and reduce the risk of disease recurrence. If the trial results are positive, this could lead to a change in the standard of care for patients with borderline resectable pancreatic cancer.
Alliance for Clinical Trials in Oncology and their pancreatic cancer trials by visiting their website at https://www.allianceforclinicaltrialsinoncology.org/.